Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 13INDUSTRY 2OTHER_GOV 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 926Neoplasms 609Breast Neoplasms 604Colorectal Neoplasms 457Neoplasm Metastasis 394Ovarian Neoplasms 328Melanoma 312Prostatic Neoplasms 311Lung Neoplasms 294Multiple Myeloma 290Recurrence 278Squamous Cell Carcinoma of Head and Neck 246Stomach Neoplasms 229Pancreatic Neoplasms 228Leukemia, Myeloid, Acute 220Triple Negative Breast Neoplasms 190Endometrial Neoplasms 190Carcinoma, Renal Cell 182Lymphoma, Non-Hodgkin 179Carcinoma, Hepatocellular 177Small Cell Lung Carcinoma 165Leukemia, Lymphocytic, Chronic, B-Cell 156Advanced Solid Tumors 154Lymphoma, Follicular 148Urinary Bladder Neoplasms 139Lymphoma, Large B-Cell, Diffuse 138Lymphoma 137Advanced Solid Tumor 137Uterine Cervical Neoplasms 134Head and Neck Neoplasms 134

Interventions

Observation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Pneumonia × 1 year × Clear all
NCT06192004 2026-05-04

LOOP

AstraZeneca

Terminated
83 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Pneumonia, Lung Diseases, Interstitial

NCT05962606 2026-03-18

Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.

Aptarion Biotech AG

Phase 2 Completed
150 enrolled
Lymphoid

Community-Acquired Pneumonia, Lymphoma, Follicular, Pneumonia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡